Flexion Aims to Treat Osteoarthritis in the Knee

Flexion Therapeutics CEO Dr. Mike Clayman on what it’s like to bring a drug to market. He talks about the drug Zilretta— for osteoarthritis of the knee. And his visit comes after a surge in stock prices amid talk that Sanofi may buy Flexion in a billion dollar deal.